FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, ...

Qiagen has announced the US Food and Drug Administration (FDA) approval of its therascreen KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug Krazati ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

“It's My Wish, We Need This Program”: Qualitative Reflections From People With High-Grade Brain Cancer Consenting to Postmortem Brain Donation Targeted therapy has transformed treatment of non–small ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...